Year: 2024
Type: article
Abstract: The 2022 WHO revision and the ICC classification have recently modified the diagnostic criteria for chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia. However, there is no consensus on whether CMML with NPM1 mutation (NPM1mut) should be diagnosed as AML. Nowadays, it is a subject of discussion because of its diagnostic and therapeutic implications. Therefore, we describe a case of a patient diagnosed with CMML NPM1mut and briefly review the literature to highlight the uncertainty about how to classify a CMML with NPM1 mutation. We emphasize the importance of a comprehensive molecular study, which is crucial to optimize the individualized treatment of patients, enabling them to access targeted therapies.
Source: The Oncologist
Authors: Sandra Castaño-Díez, José Ramón Álamo, Mònica López-Guerra, Marta Gómez-Hernando, Inés Zugasti, Carlos Jiménez-Vicente, Francesca Guijarro, Irene López-Oreja, Daniel Esteban, Paola Charry, Víctor Torrecillas, Lucia Mont-de Torres, Albert Cortés-Bullich, Álex Bataller, Ares Guardia, Daniel Munárriz, Esther Carcelero, Gisela Riu, Ana Triguero, Natalia Tovar, Dolors Vela, Silvia Beà, Dolors Costa, Dolors Colomer, Maria Rozman, Jordi Esteve, Marina Díaz-Beyá
Institutions: Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Centro de Investigación Biomédica en Red de Cáncer, Josep Carreras Leukaemia Research Institute, Hospital General de Granollers
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,045
Awards: G4548648662, Caracterización clínico-biológica de la leucemia mieloide aguda no definida molecularmente: perfil mutacional y de expresión génica, arquitectura clonal, pronóstico y sensibilidad a nuevos tratamientos, G5156664809, Análisis de la enfermedad residual medible (MRD), los mecanismos de progresión y dianas terapéuticas en la leucemia mieloide aguda tratada con nuevos regímenes de baja intensidad
OpenAlex ID: W4402972547